Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception.
Summary
Spatial and single-cell profiling reveals adaptive immune upshifts and innate downshifts during LUAD precancer evolution, with TIM-3-high signatures enriched in precancers. TIM-3 blockade at the precancer but not advanced stage reduces tumor burden and augments antigen presentation and T cell activation, nominating TIM-3 for interception strategies.
Key Findings
- Adaptive immune responses increase and innate responses relatively decrease along LUAD precancer progression.
- TIM-3-high features are enriched in LUAD precancers and decrease in later stages across human and mouse data.
- In vivo TIM-3 blockade at the precancer stage reduces tumor burden and enhances antigen presentation and T cell activation.
Clinical Implications
Supports clinical development of TIM-3 inhibitors for interception trials in high-risk LUAD precursor cohorts, with biomarker-led patient selection based on spatial/omics signatures.
Why It Matters
Defines a stage-specific immune checkpoint dependency and demonstrates functional efficacy of TIM-3 blockade for precancer interception—shifting cancer prevention paradigms toward immune-based strategies.
Limitations
- Clinical translatability requires prospective interception trials in humans.
- Potential inter-sample heterogeneity and tissue sampling bias in spatial analyses.
Future Directions
Design interception trials using TIM-3 inhibitors in biomarker-defined LUAD precursor populations and evaluate combination strategies with antigen-presentation enhancers.
Study Information
- Study Type
- Case series
- Research Domain
- Pathophysiology
- Evidence Level
- III - Observational human tissue profiling with preclinical in vivo validation in multiple mouse models.
- Study Design
- OTHER